Compare Stocks: ALB, MRNA, and ALB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALB Albemarle	$93.62 -1.3%	$103.61	$89.77 ▼ $221.00	$11.19B	1.34	2.51 million shs	1.18 million shs
ALB Albemarle	$93.62 -1.3%	$103.61	$89.77 ▼ $221.00	$11.19B	1.34	2.51 million shs	1.18 million shs
MRNA Moderna	$223.37 -3.4%	$201.67	$22.28 ▼ $280.80	$93.61B	1.16	15.52 million shs	8.04 million shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALB Albemarle	0.00%	-5.46%	-4.72%	-31.20%	-15.12%
ALB Albemarle	0.00%	-5.46%	-4.72%	-31.20%	-15.12%
MRNA Moderna	0.00%	-12.12%	-5.55%	+252.76%	+736.28%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALB Albemarle	$93.62 -1.3%	$103.61	$89.77 ▼ $221.00	$11.19B	1.34	2.51 million shs	1.18 million shs
ALB Albemarle	$93.62 -1.3%	$103.61	$89.77 ▼ $221.00	$11.19B	1.34	2.51 million shs	1.18 million shs
MRNA Moderna	$223.37 -3.4%	$201.67	$22.28 ▼ $280.80	$93.61B	1.16	15.52 million shs	8.04 million shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALB Albemarle	0.00%	-5.46%	-4.72%	-31.20%	-15.12%
ALB Albemarle	0.00%	-5.46%	-4.72%	-31.20%	-15.12%
MRNA Moderna	0.00%	-12.12%	-5.55%	+252.76%	+736.28%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALB Albemarle	2.63	Moderate Buy	$152.63	63.03% Upside
ALB Albemarle	2.63	Moderate Buy	$152.63	63.03% Upside
MRNA Moderna	2.08	Hold	$113.75	-49.08% Downside

Current Analyst Ratings Breakdown

Latest ALB, MRNA, and ALB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/12/2026	ALB Albemarle	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target		$131.00 ➝ $120.00
11/12/2026	ALB Albemarle	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target		$131.00 ➝ $120.00
11/11/2026	ALB Albemarle	CICC Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target		$83.28 ➝ $108.58
11/11/2026	ALB Albemarle	Rothschild & Co Redburn Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target		$100.00 ➝ $86.00
11/11/2026	ALB Albemarle	CICC Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target		$83.28 ➝ $108.58
11/11/2026	ALB Albemarle	Rothschild & Co Redburn Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target		$100.00 ➝ $86.00
11/9/2026	MRNA Moderna	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$230.00 ➝ $305.00
11/9/2026	ALB Albemarle	Scotiabank Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Sector Outperform	$190.00 ➝ $165.00
11/9/2026	ALB Albemarle	Scotiabank Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Sector Outperform	$190.00 ➝ $165.00
11/9/2026	ALB Albemarle	Deutsche Bank Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$155.00 ➝ $125.00
11/9/2026	ALB Albemarle	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold

(Data available from 11/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALB Albemarle	$5.14B	2.15	$6.27 per share	14.94	$72.75 per share	1.29
ALB Albemarle	$5.14B	2.15	$6.27 per share	14.94	$72.75 per share	1.29
MRNA Moderna	$1.94B	46.49	N/A	N/A	$16.90 per share	13.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALB Albemarle	-$510.63M	$4.14	22.61	10.36	0.59	10.40%	14.91%	7.58%	N/A
ALB Albemarle	-$510.63M	$4.14	22.61	10.36	0.59	10.40%	14.91%	7.58%	N/A
MRNA Moderna	-$2.82B	-$7.10	N/A	N/A	N/A	-110.46%	-25.79%	-15.85%	N/A

Latest ALB, MRNA, and ALB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/6/2026	Q3 2026	MRNA Moderna	-$1.10	$0.38	+$1.48	$0.38	$890.25 million	$1.31 billion
11/4/2026	Q3 2026	ALB Albemarle	$2.53	$2.58	+$0.05	$2.15	$1.52 billion	$1.55 billion
11/4/2026	Q3 2026	ALB Albemarle	$2.53	$2.58	+$0.05	$2.15	$1.52 billion	$1.55 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALB Albemarle	$1.64	1.75%	+1.02%	39.61%	30 Years
ALB Albemarle	$1.64	1.75%	+1.02%	39.61%	30 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A

Latest ALB, MRNA, and ALB Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
10/26/2026	ALB Albemarle	quarterly	$0.41	1.75%	12/18/2026	12/18/2026	1/4/2027
10/26/2026	ALB Albemarle	quarterly	$0.41	1.75%	12/18/2026	12/18/2026	1/4/2027

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALB Albemarle	0.21	2.34	1.57
ALB Albemarle	0.21	2.34	1.57
MRNA Moderna	0.52	3.62	3.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALB Albemarle	92.87%
ALB Albemarle	92.87%
MRNA Moderna	75.33%

Insider Ownership

Company	Insider Ownership
ALB Albemarle	0.42%
ALB Albemarle	0.42%
MRNA Moderna	10.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALB Albemarle	7,800	118.01 million	117.51 million	Optionable
ALB Albemarle	7,800	118.01 million	117.51 million	Optionable
MRNA Moderna	4,700	404.62 million	360.92 million	Optionable

ALB, MRNA, and ALB Headlines

Recent News About These Companies

MRNA (Moderna, Inc.) Investment Analysis: Can It Diversify from COVID Dependence to Respiratory, Oncology, and Rare Diseases?

4 hours ago | note.comN

Moderna to relocate UK commercial headquarters to TRIBECA in King’s Cross, London

November 14 at 8:24 AM | pharmabiz.comP

Aberdeen Group plc Buys 1,039,311 Shares of Moderna, Inc. $MRNA

November 14 at 3:08 AM | marketbeat.com

Moderna, Inc. (MRNA) - What Are Analysts Saying About This Stock?

November 14 at 2:29 AM | americanbankingnews.com

Moderna, Inc. (NASDAQ:MRNA) Stock Has Average Target Price of $113.75

November 14 at 2:28 AM | marketbeat.com

The Single Most Important Metric For Moderna Stock

November 13 at 7:19 PM | trefis.comT

Moderna (NASDAQ:MRNA) Stock Price Down 3.4% - Time to Sell?

November 13 at 5:19 PM | marketbeat.com

Moderna, Inc. (MRNA) Analyst/Investor Day - Slideshow

November 13 at 3:35 PM | seekingalpha.com

Moderna phase 3 mRNA therapy result vs BioNTech's oncology pipeline

November 13 at 2:18 PM | msn.com

Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls

November 13 at 2:18 PM | finance.yahoo.com

Promising Biotech Stocks To Consider - November 13th

November 13 at 12:13 PM | marketbeat.com

Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls

November 13 at 10:51 AM | zacks.com

Letko Brosseau & Associates Inc. Sells 551,496 Shares of Moderna, Inc. $MRNA

November 13 at 6:27 AM | marketbeat.com

Brookline Capital Markets Forecasts Moderna FY2026 Earnings

November 13 at 1:43 AM | americanbankingnews.com

Moderna Sinks 7% as Analyst Day Cancer Push Brings “$4 Billion in Cash Costs in 2027”

November 12 at 5:27 PM | finance.yahoo.com

The Next Chapter of mRNA

November 12 at 5:27 PM | time.comT

Why Is Moderna (MRNA) Joining A Global Benchmark And Publishing New Vaccine Data?

November 12 at 5:27 PM | finance.yahoo.com

Moderna (NASDAQ:MRNA) Stock Falls 7% - Here's Why

November 12 at 5:19 PM | marketbeat.com

Moderna Targets 2027 Cancer Therapy Launch, Raises 2026 Revenue Growth Outlook

November 12 at 5:13 PM | marketbeat.com

MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock?

November 12 at 1:56 PM | zacks.com

Moderna Lays Out Oncology-Driven Growth Plan at 2026 Analyst Day

November 12 at 12:26 PM | pharmexec.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ALB, MRNA, and ALB Company Descriptions

Albemarle NYSE:ALB

$93.62 -1.23 (-1.30%)

Closing price 11/13/2026 03:59 PM Eastern

Extended Trading

$93.55 -0.07 (-0.07%)

As of 11/13/2026 07:58 PM Eastern

Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services. The Specialties segment provides bromine-based specialty chemicals, including elemental bromine, alkyl and inorganic bromides, brominated powdered activated carbon, and other bromine fine chemicals; lithium specialties, such as butyllithium and lithium aluminum hydride; develops and manufactures cesium products for the chemical and pharmaceutical industries; and zirconium, barium, and titanium products for pyrotechnical applications that include airbag initiators. The Ketjen segment offers clean fuels technologies (CFT), which is composed of hydroprocessing catalysts (HPC) together with isomerization and akylation catalysts; fluidized catalytic cracking (FCC) catalysts and additives; and performance catalyst solutions (PCS), which is composed of organometallics and curatives. The company serves the energy storage, petroleum refining, consumer electronics, construction, automotive, lubricants, pharmaceuticals, and crop protection markets. Albemarle Corporation was founded in 1887 and is headquartered in Charlotte, North Carolina.

Albemarle NYSE:ALB

$93.62 -1.23 (-1.30%)

Closing price 11/13/2026 03:59 PM Eastern

Extended Trading

$93.55 -0.07 (-0.07%)

As of 11/13/2026 07:58 PM Eastern

Moderna NASDAQ:MRNA

$223.37 -7.98 (-3.45%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$217.50 -5.87 (-2.63%)

As of 11/13/2026 07:59 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALB, MRNA, and ALB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALB, MRNA, and ALB Earnings

Compare Dividends

Latest ALB, MRNA, and ALB Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALB, MRNA, and ALB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALB, MRNA, and ALB Company Descriptions

Albemarle NYSE:ALB

Albemarle NYSE:ALB

Moderna NASDAQ:MRNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALB, MRNA, and ALB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALB, MRNA, and ALB Earnings

Compare Dividends

Latest ALB, MRNA, and ALB Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALB, MRNA, and ALB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALB, MRNA, and ALB Company Descriptions

Albemarle NYSE:ALB

Albemarle NYSE:ALB

Moderna NASDAQ:MRNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools